Jonathan M. Weiss, Ph.D.
Team Member of:
Dr. Weiss is investigating the mechanisms whereby combinations of cytokines and other immune-modulating drugs, such as anti-CD40, result in the eradication of tumors. Principally, he is interested in understanding the mechanisms of leukocyte recruitment into the tumor microenvironment and the responses by these tumor-infiltrating leukocytes as they relate to tumor progression and/or metastases.
1) immunotherapy, 2) leukocytes
Contact Info
Center for Cancer Research
National Cancer Institute
Building 560; Room 31-45
Frederick, MD 21702-1201
Ph: (301) 846-5394
Fax: (301) 846-1673
weissjo@mail.nih.gov
Combination-based immunotherapies may more effectively activate cells of both innate and adaptive immune responses. Using an orthotopic mouse model of renal cell carcinoma (RENCA), I am investigating the mechanisms whereby combinations of cytokines and other immune-modulating drugs, such as anti-CD40, result in the eradication of tumors. Principally, I am interested in understanding the mechanisms of leukocyte recruitment into the tumor microenvironment and the responses by these tumor-infiltrating leukocytes as they relate to tumor progression and/or metastases.
Selected Publications
- J Immunol. 192: 5821-9, 2014. [ Journal Article ]
- Hum Immunol. 75: 614-20, 2014. [ Journal Article ]
- J Exp Med. 207: 2455-67, 2010. [ Journal Article ]
- Proc Natl Acad Sci U S A. 106: 19455-60, 2009. [ Journal Article ]
- Blood. 119: 3073-83, 2012. [ Journal Article ]
Jonathan Weiss received his Ph.D. from Albert Einstein College of Medicine in 1998, where he studied the role of chemokines and cellular adhesion molecules in mediating leukocyte transmigration across the human blood-brain barrier with Dr. Joan Berman. He was then a postdoc with Dr. Leslie Parise at the University of North Carolina Chapel Hill, where he studied the molecular regulation of platelet aggregation. He continued his postdoctoral training at the University of Virginia with Dr. Alan Horwitz, where he utilized a high-throughput screening strategy to screen for novel molecular regulators of cell adhesion and migration. After that, he spent three years as a research scientist at MaxCyte, Inc., a biotechnology company focused on the electroporation of DNA and siRNA into primary hematopoietic cells. His research there demonstrated the enhanced anti-tumor response through ex vivo loading of dendritic cells with whole tumor lysate. In 2005, he joined the Cancer and Inflammation Program where his current research focuses on the immunotherapy of renal cell carcinoma by combination cytokine therapy.